{"id":"https://openalex.org/W2741913353","doi":"https://doi.org/10.1158/1538-7445.am2017-3755","title":"Abstract 3755: Renewable and genetically engineered natural killer cells for off-the-shelf adoptive cellular immunotherapy","display_name":"Abstract 3755: Renewable and genetically engineered natural killer cells for off-the-shelf adoptive cellular immunotherapy","publication_year":2017,"publication_date":"2017-07-01","ids":{"openalex":"https://openalex.org/W2741913353","doi":"https://doi.org/10.1158/1538-7445.am2017-3755","mag":"2741913353"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2017-3755","doi":"https://doi.org/10.1158/1538-7445.am2017-3755","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2017-3755","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5011430525","display_name":"Ryan Bjordahl","orcid":"https://orcid.org/0000-0001-9277-3155","observed_orcids":["https://orcid.org/0000-0001-9277-3155"]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan Bjordahl","raw_affiliation_strings":["1Fate Therapeutics, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics, San Diego, CA;","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023014242","display_name":"Frank M. Cichocki","orcid":"https://orcid.org/0000-0003-3043-0653","observed_orcids":["https://orcid.org/0000-0003-3043-0653"]},"institutions":[{"id":"https://openalex.org/I130238516","display_name":"University of Minnesota","ror":"https://ror.org/017zqws13","country_code":"US","type":"education","lineage":["https://openalex.org/I130238516"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Frank Cichocki","raw_affiliation_strings":["2University of Minnesota Cancer Center, Minneapolis, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of Minnesota Cancer Center, Minneapolis, MN","institution_ids":["https://openalex.org/I130238516"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036327927","display_name":"Raedun L. Clarke","orcid":"https://orcid.org/0000-0002-1626-1358","observed_orcids":["https://orcid.org/0000-0002-1626-1358"]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Raedun Clarke","raw_affiliation_strings":["1Fate Therapeutics, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics, San Diego, CA;","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054016372","display_name":"Svetlana Gaidarova","orcid":"https://orcid.org/0000-0003-2793-8472","observed_orcids":["https://orcid.org/0000-0003-2793-8472"]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Svetlana Gaidarova","raw_affiliation_strings":["1Fate Therapeutics, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics, San Diego, CA;","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025807763","display_name":"Brian C. Groff","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian Groff","raw_affiliation_strings":["1Fate Therapeutics, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics, San Diego, CA;","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064341938","display_name":"Paul Rogers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul Rogers","raw_affiliation_strings":["1Fate Therapeutics, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics, San Diego, CA;","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101198632","display_name":"Stacey K. Moreno","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stacey Moreno","raw_affiliation_strings":["1Fate Therapeutics, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics, San Diego, CA;","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057388168","display_name":"Ramzey Abujarour","orcid":"https://orcid.org/0000-0002-7849-9441","observed_orcids":["https://orcid.org/0000-0002-7849-9441"]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ramzey Abujarour","raw_affiliation_strings":["1Fate Therapeutics, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics, San Diego, CA;","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031074371","display_name":"Greg Bonello","orcid":"https://orcid.org/0000-0002-8756-4137","observed_orcids":["https://orcid.org/0000-0002-8756-4137"]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Greg Bonello","raw_affiliation_strings":["1Fate Therapeutics, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics, San Diego, CA;","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103253648","display_name":"Tom Lee","orcid":"https://orcid.org/0000-0003-0805-4006","observed_orcids":["https://orcid.org/0000-0003-0805-4006"]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tom Lee","raw_affiliation_strings":["1Fate Therapeutics, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics, San Diego, CA;","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003575906","display_name":"Weijie Lan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Weijie Lan","raw_affiliation_strings":["1Fate Therapeutics, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics, San Diego, CA;","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007922002","display_name":"Matthieu Bauer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthieu Bauer","raw_affiliation_strings":["1Fate Therapeutics, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics, San Diego, CA;","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077081720","display_name":"Dave Robbins","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dave Robbins","raw_affiliation_strings":["1Fate Therapeutics, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics, San Diego, CA;","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039651671","display_name":"Betsy Rezner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Betsy Rezner","raw_affiliation_strings":["1Fate Therapeutics, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics, San Diego, CA;","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101974554","display_name":"Sarah Cooley","orcid":"https://orcid.org/0000-0001-8953-6730","observed_orcids":["https://orcid.org/0000-0001-8953-6730"]},"institutions":[{"id":"https://openalex.org/I130238516","display_name":"University of Minnesota","ror":"https://ror.org/017zqws13","country_code":"US","type":"education","lineage":["https://openalex.org/I130238516"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarah Cooley","raw_affiliation_strings":["2University of Minnesota Cancer Center, Minneapolis, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of Minnesota Cancer Center, Minneapolis, MN","institution_ids":["https://openalex.org/I130238516"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022682897","display_name":"Bruce K. Walcheck","orcid":"https://orcid.org/0000-0003-1933-3887","observed_orcids":["https://orcid.org/0000-0003-1933-3887"]},"institutions":[{"id":"https://openalex.org/I130238516","display_name":"University of Minnesota","ror":"https://ror.org/017zqws13","country_code":"US","type":"education","lineage":["https://openalex.org/I130238516"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bruce Walcheck","raw_affiliation_strings":["2University of Minnesota Cancer Center, Minneapolis, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of Minnesota Cancer Center, Minneapolis, MN","institution_ids":["https://openalex.org/I130238516"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083400753","display_name":"Stewart E. Abbot","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stewart Abbot","raw_affiliation_strings":["1Fate Therapeutics, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics, San Diego, CA;","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058268746","display_name":"Bruce R. Blazar","orcid":"https://orcid.org/0000-0002-9608-9841","observed_orcids":["https://orcid.org/0000-0002-9608-9841"]},"institutions":[{"id":"https://openalex.org/I130238516","display_name":"University of Minnesota","ror":"https://ror.org/017zqws13","country_code":"US","type":"education","lineage":["https://openalex.org/I130238516"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bruce Blazar","raw_affiliation_strings":["2University of Minnesota Cancer Center, Minneapolis, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of Minnesota Cancer Center, Minneapolis, MN","institution_ids":["https://openalex.org/I130238516"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036153760","display_name":"Scott Wolchko","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott Wolchko","raw_affiliation_strings":["1Fate Therapeutics, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics, San Diego, CA;","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109439004","display_name":"Daniel D. Shoemaker","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Shoemaker","raw_affiliation_strings":["1Fate Therapeutics, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics, San Diego, CA;","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027151969","display_name":"Jeffrey S. Miller","orcid":"https://orcid.org/0000-0002-0339-4944","observed_orcids":["https://orcid.org/0000-0002-0339-4944"]},"institutions":[{"id":"https://openalex.org/I130238516","display_name":"University of Minnesota","ror":"https://ror.org/017zqws13","country_code":"US","type":"education","lineage":["https://openalex.org/I130238516"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey S. Miller","raw_affiliation_strings":["2University of Minnesota Cancer Center, Minneapolis, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of Minnesota Cancer Center, Minneapolis, MN","institution_ids":["https://openalex.org/I130238516"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5070964738","display_name":"Bahram Bob Valamehr","orcid":"https://orcid.org/0000-0002-5917-3585","observed_orcids":["https://orcid.org/0000-0002-5917-3585"]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bahram Valamehr","raw_affiliation_strings":["1Fate Therapeutics, San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics, San Diego, CA;","institution_ids":["https://openalex.org/I4210155835"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"77","issue":"13_Supplement","first_page":"3755","last_page":"3755"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11020","display_name":"Immune Cell Function and Interaction","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11020","display_name":"Immune Cell Function and Interaction","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/natural-killer-cells","display_name":"natural killer cells","score":0.8529999852180481},{"id":"https://openalex.org/keywords/induced-pluripotent-stem-cells","display_name":"induced pluripotent stem cells","score":0.8830000162124634},{"id":"https://openalex.org/keywords/cd16","display_name":"CD16","score":0.5450000166893005},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.8640000224113464},{"id":"https://openalex.org/keywords/nk-cell-engineering","display_name":"NK cell engineering","score":0.6069999933242798},{"id":"https://openalex.org/keywords/ipsc-derived-nk-cells","display_name":"iPSC-derived NK cells","score":0.7710000276565552},{"id":"https://openalex.org/keywords/nk-cell-expansion","display_name":"NK cell expansion","score":0.6980000138282776},{"id":"https://openalex.org/keywords/telomere-length","display_name":"telomere length","score":0.9279999732971191},{"id":"https://openalex.org/keywords/immunosuppressive-proteins","display_name":"immunosuppressive proteins","score":0.6679999828338623},{"id":"https://openalex.org/keywords/nk-cell-persistence","display_name":"NK cell persistence","score":0.734000027179718},{"id":"https://openalex.org/keywords/nk-cell-reprogramming","display_name":"NK cell reprogramming","score":0.38199999928474426},{"id":"https://openalex.org/keywords/perforin","display_name":"perforin","score":0.39800000190734863}],"concepts":[{"id":"https://openalex.org/C2778867473","wikidata":"https://www.wikidata.org/wiki/Q17544382","display_name":"NKG2D","level":4,"score":0.6831825375556946},{"id":"https://openalex.org/C2781462264","wikidata":"https://www.wikidata.org/wiki/Q78482053","display_name":"CD16","level":5,"score":0.6034259796142578},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5755463242530823},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.571670413017273},{"id":"https://openalex.org/C40677261","wikidata":"https://www.wikidata.org/wiki/Q21418091","display_name":"Antibody-dependent cell-mediated cytotoxicity","level":4,"score":0.5505495667457581},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5499064326286316},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5240671634674072},{"id":"https://openalex.org/C2778102761","wikidata":"https://www.wikidata.org/wiki/Q332181","display_name":"Natural killer cell","level":4,"score":0.4689317047595978},{"id":"https://openalex.org/C28651165","wikidata":"https://www.wikidata.org/wiki/Q4259786","display_name":"Lymphokine-activated killer cell","level":5,"score":0.4287850260734558},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.41653403639793396},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.3915717899799347},{"id":"https://openalex.org/C129374314","wikidata":"https://www.wikidata.org/wiki/Q909381","display_name":"Interleukin 21","level":4,"score":0.380810022354126},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.36212530732154846},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.3427163362503052},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.3346005082130432},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.3313726484775543},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.27593937516212463},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.17933592200279236},{"id":"https://openalex.org/C114684123","wikidata":"https://www.wikidata.org/wiki/Q419458","display_name":"CD3","level":4,"score":0.14609986543655396},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.12590879201889038},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.07033368945121765}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2017-3755","doi":"https://doi.org/10.1158/1538-7445.am2017-3755","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2017-3755","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2998337455","https://openalex.org/W2784994984","https://openalex.org/W2886559923","https://openalex.org/W2759588376","https://openalex.org/W2995447672","https://openalex.org/W3200157938","https://openalex.org/W4310258433","https://openalex.org/W2964205145","https://openalex.org/W4412186453","https://openalex.org/W4237617979"],"abstract_inverted_index":{"Abstract":[0],"The":[1,311],"unique":[2,85],"attributes":[3],"of":[4,40,55,60,69,94,118,146,176,188,202,260,291,330,339,350,379,463],"a":[5,22,26,84,91,156,171,192,307],"combinatorial":[6,79],"tumor":[7,273],"recognition":[8],"system,":[9],"diminished":[10],"off-tumor":[11],"cytotoxicity,":[12],"and":[13,65,78,86,105,116,143,191,206,241,265,268,281,336,360,398,449],"multifaceted":[14],"effector":[15],"function":[16,48],"make":[17],"natural":[18,452],"killer":[19,453],"(NK)":[20],"cells":[21,35,98,123,166,184,250,276,293,352,381,454],"prime":[23],"candidate":[24],"for":[25,76,140,455,467],"universal":[27],"approach":[28],"to":[29,89,162,168,210,220,247,257,286,296,302,353,361],"cancer":[30,80],"immunotherapy.":[31],"In":[32,179,208,255,368],"addition,":[33],"NK":[34,46,97,122,148,165,195,225,235,249,387],"are":[36],"the":[37,53,58,61,66,74,136,141,182,214,252,261,344,348,356,365,370,376,464],"principal":[38],"mediator":[39],"antibody-directed":[41],"cellular":[42,458],"cytotoxicity":[43,271],"(ADCC).":[44],"However,":[45],"cell":[47,132,160,196,226],"is":[49],"often":[50],"impaired":[51],"in":[52,284,317,325,364],"setting":[54],"cancer,":[56],"reducing":[57],"effectiveness":[59],"endogenous":[62,211],"immune":[63],"system":[64],"therapeutic":[67,377],"efficacy":[68],"monoclonal":[70],"antibodies.":[71],"To":[72],"address":[73],"need":[75],"advanced":[77],"therapies,":[81],"we":[82,154],"developed":[83],"effective":[87],"strategy":[88],"create":[90],"renewable":[92],"source":[93],"engineered":[95,147,167,215,342,451],"\u201coff-the-shelf\u201d":[96,386],"with":[99,110,320,391],"augmented":[100,392],"function,":[101],"including":[102],"enhanced":[103,243,269],"ADCC":[104,279],"persistence.":[106],"Key":[107],"challenges":[108],"associated":[109,319],"genetic":[111],"editing,":[112],"limited":[113],"expansion,":[114],"persistence":[115,363],"variability":[117],"peripheral":[119],"blood":[120],"(PB)-derived":[121],"were":[124],"overcome":[125,355],"by":[126,200],"utilizing":[127],"our":[128],"induced":[129],"pluripotent":[130],"stem":[131],"(iPSC)":[133],"technology":[134],"as":[135,198,382],"unlimited":[137],"starting":[138],"material":[139],"reproducible":[142],"consistent":[144],"derivation":[145],"cells.":[149,327],"Through":[150],"targeted":[151],"transgene":[152],"integration,":[153],"produced":[155],"clonal":[157],"iPSC":[158,345],"master":[159],"line":[161],"continuously":[163],"produce":[164],"uniformly":[169],"express":[170],"high":[172],"affinity,":[173],"non-cleavable":[174],"version":[175],"CD16":[177,189,212,287],"(hnCD16-NK).":[178],"directed":[180],"differentiation,":[181],"hnCD16-NK":[183,230,275,292,326,351],"displayed":[185,277],"homogeneous":[186],"expression":[187,201,259,338],"(>95%)":[190],"mature":[193],"CD56+":[194],"phenotype,":[197],"exhibited":[199],"KIR,":[203],"NCRs,":[204],"DNAM-1,":[205],"NKG2D.":[207],"contrast":[209],"expression,":[213],"hnCD16":[216],"molecule":[217],"was":[218,294],"shown":[219],"be":[221,297,316],"cleavage":[222],"resistant":[223],"upon":[224,237],"activation":[227],"(>95%":[228],"CD16+":[229,233],"vs.":[231],"<10%":[232],"PB-derived":[234,248],"cell,":[236],"target":[238],"cell-mediated":[239],"activation),":[240],"demonstrated":[242],"antibody":[244],"binding":[245],"compared":[246],"expressing":[251],"low-affinity":[253],"variant.":[254],"addition":[256],"increased":[258],"cytolytic":[262],"molecules":[263,335],"perforin":[264],"granzyme":[266],"B":[267],"direct":[270],"against":[272],"targets,":[274],"superior":[278],"capacity":[280,314],"cytokine":[282],"production":[283],"response":[285],"stimulation.":[288],"Importantly,":[289],"manufacture":[290],"proven":[295],"highly":[298],"scalable,":[299],"delivering":[300],"up":[301],"107":[303],"fold":[304],"expansion":[305],"over":[306],"35":[308],"day":[309],"period.":[310],"maintained":[312],"proliferative":[313],"can":[315],"part":[318],"longer":[321],"telomere":[322],"length":[323],"seen":[324],"Furthermore,":[328],"deletion":[329],"classical":[331],"human":[332],"leukocyte":[333],"antigen":[334],"ectopic":[337],"immunosuppressive":[340],"proteins":[341],"at":[343],"level":[346],"provided":[347],"ability":[349],"potentially":[354],"host":[357],"histocompatibility":[358],"barrier":[359],"improve":[362],"allogeneic":[366],"setting.":[367],"conclusion,":[369],"preclinical":[371,399],"data":[372],"presented":[373],"herein":[374],"highlight":[375],"value":[378],"hnCD16-iNK":[380],"an":[383],"ideal":[384],"ADCC-mediated":[385],"cell-based":[388],"immunotherapeutic":[389],"product":[390],"persistence,":[393],"anti-tumor":[394],"capacity,":[395],"manufacturing":[396],"reliability":[397],"efficacy.":[400],"Citation":[401],"Format:":[402],"Ryan":[403],"Bjordahl,":[404],"Frank":[405],"Cichocki,":[406],"Raedun":[407],"Clarke,":[408],"Svetlana":[409],"Gaidarova,":[410],"Brian":[411],"Groff,":[412],"Paul":[413],"Rogers,":[414],"Stacey":[415],"Moreno,":[416],"Ramzey":[417],"Abujarour,":[418],"Greg":[419],"Bonello,":[420],"Tom":[421],"Lee,":[422],"Weijie":[423],"Lan,":[424],"Matthieu":[425],"Bauer,":[426],"Dave":[427],"Robbins,":[428],"Betsy":[429],"Rezner,":[430],"Sarah":[431],"Cooley,":[432],"Bruce":[433,437],"Walcheck,":[434],"Stewart":[435],"Abbot,":[436],"Blazar,":[438],"Scott":[439],"Wolchko,":[440],"Daniel":[441],"Shoemaker,":[442],"Jeffrey":[443],"S.":[444],"Miller,":[445],"Bahram":[446],"Valamehr.":[447],"Renewable":[448],"genetically":[450],"off-the-shelf":[456],"adoptive":[457],"immunotherapy":[459],"[abstract].":[460],"In:":[461],"Proceedings":[462],"American":[465],"Association":[466],"Cancer":[468,481],"Research":[469],"Annual":[470],"Meeting":[471],"2017;":[472],"2017":[473],"Apr":[474],"1-5;":[475],"Washington,":[476],"DC.":[477],"Philadelphia":[478],"(PA):":[479],"AACR;":[480],"Res":[482],"2017;77(13":[483],"Suppl):Abstract":[484],"nr":[485],"3755.":[486],"doi:10.1158/1538-7445.AM2017-3755":[487]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2017-08-08T00:00:00"}